During this week’s European League Against Rheumatism Annual European Congress of Rheumatology, researchers will present on the long-term safety, immunogenicity, and efficacy of the biosimilar versus the reference in an open-label extension study that involved switching between the biosimilar and the reference.
Mylan’s adalimumab biosimilar, developed by Fujifilm Kyowa Kirin Biologics and recently approved and launched in the European Union, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the basis of data including those from a phase 3 clinical trial comparing the biosimilar to its reference (Humira) in patients with rheumatoid arthritis (RA).
During this week’s European League Against Rheumatism Annual European Congress of Rheumatology, researchers will present on the long-term safety, immunogenicity, and efficacy of the biosimilar versus the reference in an open-label extension study that involved switching between the biosimilar and the reference.1
In the open-label extension, 645 patients with RA who completed the phase 3 clinical trial with clinical response and without serious adverse events (AEs) received the biosimilar through week 76. Pooled data were analyzed up to 2 years.
In total, 216 patients received the biosimilar only for 3 treatment periods; 108 received the biosimilar, switched to the reference, then switched to the biosimilar; 108 started with the reference, then received the biosimilar for 2 treatment periods; and 213 received the reference for 2 treatment periods before switching to the biosimilar.
Across the 4 groups described above, the percentages of patients who achieved response were as follows:
In total, the following percentages of patients tested positive for anti-drug antibodies (ADA) across the 4 groups, respectively: 51.9%, 61.0%, 45.2%, and 51.6%. The majority of patients with positive ADA status had neutralizing activity.
According to the authors, the safety, immunogenicity, and efficacy of the biosimilar were maintained over long-term treatment and after switching.
Separately, a research team also reported on injection-site pain linked with the administration of the biosimilar versus the reference, saying that the biosimilar had a clear advantage over the brand-name Humira in terms of pain related to administration.2
The researchers pooled data from 4 studies on the biosimilar—which has different excipients from the reference—in patients with RA and in healthy volunteers. Data were analyzed from a total of 2007 assessments in 1001 individuals.
A linear mixed model of the visual analog scale showed a 12.6-point lower pain score for the biosimilar than for the reference (95% CI, —14.3 to –10.8; P <.001). For the autoinjector and prefilled syringe presentations of the biosimilar, the autoinjector had a 1.7-point lower pain score compared with prefilled syringe (95% CI, —3.3 to –0.1; P = .035).
The biosimilar, write the authors, has a “significant advantage” over the reference adalimumab in terms of injection pain.
References
1. Alten R, Genovese MC, Muninz AR, Kellner H. Long-term safety, immunogenicity and efficacy in randomized, double-blind, and open-label extension studies comparing FKB327, an adalimumab biosimilar, with the adalimumab reference product in patients with rheumatoid arthritis. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019, June 12-15, 2019; Madrid, Spain. Abstract SAT0132.
2. Alten R, Genovese MC, Boyce M, Yonemura T, Ito T, Kellner H. Systematic analysis of injection-site pain caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus administration of the adalimumab reference product via different delivery methods. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019, June 12-15, 2019; Madrid, Spain. Abstract FRI0075.
Cost and Efficacy Insights on Infliximab Biosimilars in Pediatric Uveitis
December 3rd 2024The study highlights the safety, efficacy, and cost benefits of infliximab biosimilars in managing pediatric noninfectious uveitis, showing fewer disease flares and reduced costs compared with reference infliximab, as well as the influence of insurance mandates on treatment decisions.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data
November 19th 2024The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.